Compare PECO & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PECO | TWST |
|---|---|---|
| Founded | 1991 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.2B |
| IPO Year | 2010 | 2018 |
| Metric | PECO | TWST |
|---|---|---|
| Price | $43.30 | $91.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 8 |
| Target Price | $39.71 | ★ $46.88 |
| AVG Volume (30 Days) | 849.1K | ★ 1.5M |
| Earning Date | 04-23-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.26% | N/A |
| EPS Growth | ★ 74.51 | 63.89 |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $726,594,000.00 | $376,572,000.00 |
| Revenue This Year | $5.82 | $18.91 |
| Revenue Next Year | $3.81 | $15.07 |
| P/E Ratio | $177.83 | ★ N/A |
| Revenue Growth | 9.86 | ★ 20.32 |
| 52 Week Low | $32.84 | $23.30 |
| 52 Week High | $44.38 | $105.47 |
| Indicator | PECO | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 59.67 | 52.65 |
| Support Level | $38.92 | $86.30 |
| Resistance Level | $44.38 | $105.47 |
| Average True Range (ATR) | 0.69 | 6.31 |
| MACD | 0.01 | -1.21 |
| Stochastic Oscillator | 60.22 | 38.28 |
Phillips Edison & Co Inc is a real estate investment trust. The company also operates a third-party investment management business providing property management and advisory services to four unconsolidated institutional joint ventures, in which it has a partial ownership interest, and one private fund. It invests in well-occupied, grocery-anchored neighborhood and community shopping centers. It holds an integrated in-house operating platform built on a market of expertise designed to optimize property value and consistently deliver a great shopping experience.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.